West Pharmaceutical Services (NYSE:WST) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $158.00 price target on the medical instruments supplier’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 16.55% from the stock’s previous close.
According to Zacks, “West Pharmaceutical Services, Inc. is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products. West is the world’s premiere provider of standard-setting systems and device components for parenterally administered medicines and an emerging leader in the development of advanced formulation technologies for the transmucosal delivery of drugs. West contract manufacturing harnesses a powerful combination of innovation, technology, infrastructure and expertise to serve the pharmaceutical, medical and consumer industries. Along with more than 50 years of experience, they bring customers quality, safety and reliability in injection molding, contract assembly and finished packaging. “
WST has been the topic of a number of other reports. William Blair initiated coverage on West Pharmaceutical Services in a report on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 target price on the stock. Bank of America raised West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a report on Friday, July 26th. Finally, Jefferies Financial Group cut West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 target price on the stock. in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $130.72.
West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.17. West Pharmaceutical Services had a return on equity of 16.93% and a net margin of 12.94%. The company had revenue of $469.70 million for the quarter, compared to analysts’ expectations of $459.90 million. During the same period last year, the firm earned $0.70 EPS. West Pharmaceutical Services’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts anticipate that West Pharmaceutical Services will post 3.07 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in WST. Financial Gravity Wealth Inc. purchased a new stake in West Pharmaceutical Services in the 1st quarter worth $25,000. Manchester Capital Management LLC purchased a new stake in West Pharmaceutical Services in the 1st quarter worth $33,000. Quadrant Capital Group LLC increased its stake in West Pharmaceutical Services by 208.7% in the 1st quarter. Quadrant Capital Group LLC now owns 318 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 215 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth $40,000. Finally, Machina Capital S.A.S. purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth $42,000. 91.62% of the stock is currently owned by institutional investors.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Read More: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.